Azacitidine Patent Expiration
Azacitidine is Used for continued treatment of adults with acute myeloid leukemia who achieved first complete remission following intensive chemotherapy. It was first introduced by Bristol-Myers Squibb Co
Azacitidine Patents
Given below is the list of patents protecting Azacitidine, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Onureg | US8846628 | Oral formulations of cytidine analogs and methods of use thereof | Jun 03, 2030 | Bristol |
| Onureg | US11571436 | Oral formulations of cytidine analogs and methods of use thereof | May 14, 2029 | Bristol |
| Onureg | US12053482 | Oral formulations of cytidine analogs and methods of use thereof | May 14, 2029 | Bristol |
Azacitidine's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List